The most important thing in real estate is "location, location, location" -- but in the pharmaceutical industry it's "innovation, innovation, innovation." Drugmaker AstraZeneca is grappling with the effects of some massive drug patent expirations and is under pressure to innovate quickly. The week, the company's recently appointed CEO changed up both personnel and structure in his management team. In this video, our health-care analysts discuss these changes and how they might jump-start an R&D revolution at the company.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Is This the Start of an AstraZeneca Revolution? originally appeared on Fool.com.David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.